Table 3.
Adverse events.
| Nefopam (n = 22) | Ketamine (n = 22) | Control (n = 21) | P | |
|---|---|---|---|---|
| Nausea or Vomiting | 12 | 8 | 4 | NS |
| Tachycardia | 8 | 2 | 3 | < 0.005 |
| Profuse Sweating | 4 | 0 | 0 | < 0.05 |
| Dry Mouth | 4 | 0 | 1 | NS |
| Dysphoria | 0 | 1 | 0 | NS |
| Diplopia | 0 | 2 | 2 | NS |
| Dizziness | 1 | 4 | 1 | NS |
Results presented as number of patients. Tachycardia and profuse sweating were most frequent in the Nefopam group.